Director
Landmark Bio
Watertown
Robert K. Delong (Rob), MS, PhD, serves as Director of mRNA Technology at Landmark Bio (LMB), working with partners to advance their RNA and nanoparticle-based projects and collaborating internally to support platform development and manufacturing. Before LMB, he spent 15+ years in academia, receiving tenure in biomedical sciences at Missouri State University, then moving to Kansas State University as faculty co-founder of the Nanotechnology Innovation Center. Earlier in his career, he worked at Megabios (merged with GeneMedicine), PowderJect Vaccines and helped launch an antisense oligo start-up coming out of the Lineberger Cancer Institute later acquired by Avi Biopharma (now Sarepta). Over the years, Rob’s groups have worked on antisense, siRNA, gene therapy, DNA vaccine and more recently mRNA vaccine, characterization and delivery by lipid, polymer, inorganic and hybrid systems, formulation development and pre-clinical to clinical translation. Rob has produced over 100 intellectual products including; patents, research publications, review articles, book chapters, a textbook and conference abstracts co-published with over 140 co-authors including 14 thesis completing students. Rob earned a masters in chemistry from the University of Rochester, PhD in Biochemistry and Biophysics at Johns Hopkins University and did post-doctoral work in pharmacology at the University of North Carolina-Chapel Hill.
Disclosure information not submitted.
Beyond mRNA and Lipid Nanoparticles: Formulation and Process Innovations
Tuesday, May 14, 2024
3:00 PM – 3:15 PM PT